TABLE 4.

Characteristics of the two patients who experienced adverse events (AEs).

	Age (years)/sex	AEs	Severity grade	Pancreatic duct dilation	Tumor involvement at the orifice of the cystic duct	Stent diameter (mm)	Stent length (mm)	Stent placement type	Pancreatic duct stent placement to prevent PEP	Prophylactic rectal NSAID use	Treatment
1	81/female	Pancreatitis	Mild	No	No	10	6	Across the papilla	No	No	Conservative therapy
2	81/female	Cholangitis	Mild	No	Yes	8	8	Above the papilla	No	No	Conservative therapy

Abbreviations: AEs, adverse events; NSAID, non‐steroidal anti‐inflammatory drug; PEP, post‐endoscopic retrograde cholangiopancreatography pancreatitis.